双氯芬酸可预防糖尿病患者白内障手术后黄斑增厚的早期事件。
Diclofenac prevents an early event of macular thickening after cataract surgery in patients with diabetes.
作者信息
Shimura Masahiko, Nakazawa Toru, Yasuda Kanako, Nishida Kohji
机构信息
Department of Ophthalmology, NTT East Japan Tohoku Hospital, Sendai, Japan.
出版信息
J Ocul Pharmacol Ther. 2007 Jun;23(3):284-91. doi: 10.1089/jop.2006.134.
PURPOSE
This study compares the effect of topical diclofenac with that of betamethasone against postoperative cystoid macular edema (CME) following cataract surgery in patients with non- and mild nonproliferative diabetic retinopathy.
METHODS
Forty-six (46) consecutive patients with mild nonproliferative- or nondiabetic retinopathy who had bilateral and symmetrical cataracts underwent uncomplicated cataract surgery in both eyes (92 eyes in total). Postoperatively, topical diclofenac was applied 4 times daily for 1 eye, and topical betamethasone 4 times daily for the other eye in each patient. Best corrected logMAR visual acuity (BCVA), averaged foveal thickness (FT) as measured by optical coherence tomography (OCT), and intraocular pressure (IOP) were monitored preoperatively, and also postoperatively at 1 day and 1, 4, and 8 weeks.
RESULTS
VA in both the diclofenac- and betamethasone-treated eyes significantly improved following the cataract surgery; however, no statistical difference of VA was noted between the diclofenac- and betamethasone-treated eyes throughout the observational period (before and after the surgery until 8 weeks postoperatively). FT in both eyes increased after the cataract surgery. FT in the diclofenac-treated eyes did not increase 1 week after surgery, but gradually increased at week 4 and week 8. In contrast, the FT in the betamethasone-treated eyes increased during 1-8 weeks postoperatively. IOP in the diclofenac-treated eyes decreased with time, but IOP in the betamethasone-treated eyes showed no change throughout the observational period.
CONCLUSIONS
Postoperative macular thickening following cataract surgery in patients with non- or mild nonproliferative-diabetic retinopathy cannot be fully suppressed by either topical diclofenac or betamethasone. Nonetheless, diclofenac protected against an early event of postoperative CME and also a decrease of IOP.
目的
本研究比较双氯芬酸与倍他米松局部用药对非增殖性糖尿病视网膜病变和轻度非增殖性糖尿病视网膜病变患者白内障手术后囊样黄斑水肿(CME)的影响。
方法
46例患有轻度非增殖性或非糖尿病性视网膜病变且双眼患有双侧对称性白内障的连续患者接受了双眼无并发症的白内障手术(共92只眼)。术后,每位患者一只眼每日局部应用双氯芬酸4次,另一只眼每日局部应用倍他米松4次。术前以及术后1天、1周、4周和8周监测最佳矫正对数最小分辨角视力(BCVA)、光学相干断层扫描(OCT)测量的平均中央凹厚度(FT)和眼压(IOP)。
结果
白内障手术后,双氯芬酸治疗组和倍他米松治疗组的视力均显著改善;然而,在整个观察期(手术前后直至术后8周),双氯芬酸治疗组和倍他米松治疗组的视力无统计学差异。白内障手术后双眼的FT均增加。双氯芬酸治疗组的眼睛在术后1周FT未增加,但在第4周和第8周逐渐增加。相比之下,倍他米松治疗组的眼睛在术后1 - 8周FT增加。双氯芬酸治疗组的眼压随时间降低,但倍他米松治疗组的眼压在整个观察期无变化。
结论
非增殖性或轻度非增殖性糖尿病视网膜病变患者白内障手术后的黄斑增厚不能被局部应用双氯芬酸或倍他米松完全抑制。尽管如此,双氯芬酸可预防术后CME的早期发生以及眼压降低。